Novo Nordisk announced that it would acquire Dicerna, a biopharmaceutical company focusing on ribonucleic acid interference (RNAi) technology, for approximately $3.3 billion on 18 November 2021. This blockbuster deal will give Novo Nordisk rights to Dicerna’s GalXC RNAi platform, which is designed to enable access to intracellular disease targets across hepatic and extrahepatic cell and tissue types. Source: Biopharm International 18/11/2021